Argos Therapeutics Inc (NASDAQ:ARGS)
Shares of Argos Therapeutics Inc (NASDAQ:ARGS) rallied 12.65% after the company confirmed the dosing of the first HIV patient with AGS-004 dendritic cell therapy. The Phase 2 HIV eradication trial is being conducted in partnership with the University of North Carolina.
ARGS Stock Performance
The patient dosing marks the first time that an HIV patient has received a therapy utilizing RNA antigens from his latent lateral reservoir. The news did little to reverse the direction of ARGS stock as it continues to languish around all-time lows.
The stock is currently trading in a tight $0.21 – $0.25 per share range. Argos Therapeutics Inc (NASDAQ:ARGS) has underperformed the overall industry having shed more than 80% in market value since the start of the year. It awaits to be seen if the HIV trial is the catalyst that will help push the stock up from the current trading levels.
The use of the RNA antigens from the patient’s latent reservoir was prompted by the fact the latent reservoir is where the HIV virus is most dominant, hidden from attack by the immune system. Current treatments agents have struggled to target the HIV virus in the reservoir rendering them inefficient.
The ongoing trial seeks to test whether boosting antiviral immunity with AGS-004, known to stimulate T-cells that attack HIV infected cells, will help expose the virus to the immune system to facilitate their eradication. According to Argos Therapeutics Inc. (NASDAQ:ARGS), the isolation of specific viral antigens from patients own could enable more focused immune system attack on the HIV virus.
“We believe that the new manufacturing process may allow AGS-004 to generate immune responses that are much better matched to the viral variants that will emerge during latency reversal with vorinostat treatment and, therefore, maximize the opportunity for viral clearance,” said Charles Nicolette, Chief Scientific Officer of Argos.
Argos Therapeutics Inc (NASDAQ:ARGS) has already enrolled four patients who will receive the AGS-004 manufactured using RNA antigens derived from infectious plasma. Results from ongoing Phase 2 eradication trial continues to be well tolerated.
Argos Therapeutics Inc (NASDAQ:ARGS) is funding the AGS-004 trial with finances provided by the National Institute of Health and the National Institute of Allergy and Infectious Diseases as well as Collaboratory of Research for Aids Eradication.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.